Granted Patent B2

US 12,679,851 · App. 18/009,481 · Granted Jul 14, 2026

Inventor: Shuhui Chen (Shanghai, CN)

Assignee: TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.

C07D513/04A61P3/10C07D519/00

Abstract

Claims (33)

1 . A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

wherein,

is selected from a single bond and a double bond, and when T 2 is selected from N, is a single bond;

T 1 and T 2 are selected from N and CH;

X 1 and X 2 are each independently selected from CH, N, O, and S;

X 3 is a single bond;

L 1 is selected from a single bond and —C 1-3 alkyl-;

R 1 is selected from F, Cl, Br, I, OH, NH 2 , and CN;

m is selected from 0, 1, 2, 3, 4, and 5;

R 2 is selected from

and the

are optionally substituted by 1, 2, or 3 R a ;

Y 1 and Y 2 are each independently selected from CH, CH 2 , N, NH, and O;

o and p are each independently selected from 0, 1, 2, and 3;

R 3 is selected from —C(═O)—NH—R b , —C(═O)—R b , —S(═O) 2 —NH—R b , and —S(═O) 2 —R b ;

R 5 is selected from F, Cl, Br, I, and C 1-3 alkyl;

n is selected from 0, 1, and 2;

or the structura; moiety

is

R 4 is selected from H, F, Cl, Br, I. and CH 3 ;

R a is selected from F, Cl, Br, and I;

R b is selected from OH, CN, C 1-3 alkyl, and C 1-3 alkoxy, C 1-3 alkyl and C 1-3 alkyl and C 1-3 alkoxy are optionally substituted by 1, 2, or 3 R;

R is selected from F, Cl, and Br.

2 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the structural moiety

is selected from

3 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the structural moiety

is N selected from

4 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is selected from:

wherein,

is selected from a single bond and a double bond, and when T 2 is N, is a single bond.

5 . A method for activating GLP-1 receptor in a subject in need thereof, comprising: administering an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.

6 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , selected from

7 . The compound or the pharmaceutically acceptable salt thereof according to claim 6 , which is selected from:

Assignments (3)

Priority Claims (3)

Continuity (1)

References Cited (16)